Chuck Royce's SPRY Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 207,051 shares of ARS Pharmaceuticals, Inc. (SPRY) worth $2.41 M, representing 0.02% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Chuck Royce has maintained a strategic position in SPRY, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 238,158 shares. Largest reduction occurred in Q2 2025, reducing 386,497 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's ARS Pharmaceuticals (SPRY) Holding Value Over Time
Track share changes against reported price movement
Quarterly ARS Pharmaceuticals (SPRY) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2023 | +303,900 | New Buy | 303,900 | $6.51 |
| Q2 2023 | +159,800 | Add 52.58% | 463,700 | $6.70 |
| Q4 2023 | +10,000 | Add 2.16% | 473,700 | $5.48 |
| Q1 2024 | +85,000 | Add 17.94% | 558,700 | $10.22 |
| Q2 2024 | +87,000 | Add 15.57% | 645,700 | $8.51 |
| Q3 2024 | +45,755 | Add 7.09% | 691,455 | $14.50 |
| Q4 2024 | +238,158 | Add 34.44% | 929,613 | $10.55 |
| Q1 2025 | -286,847 | Reduce 30.86% | 642,766 | $12.58 |
| Q2 2025 | -386,497 | Reduce 60.13% | 256,269 | $17.45 |
| Q3 2025 | -256,269 | Sold Out | 0 | $0.00 |
| Q4 2025 | +207,051 | New Buy | 207,051 | $11.65 |
Chuck Royce's ARS Pharmaceuticals Investment FAQs
Chuck Royce first purchased ARS Pharmaceuticals, Inc. (SPRY) in Q1 2023, acquiring 303,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held ARS Pharmaceuticals, Inc. (SPRY) for 12 quarters since Q1 2023.
Chuck Royce's largest addition to ARS Pharmaceuticals, Inc. (SPRY) was in Q1 2023, adding 303,900 shares worth $1.98 M.
According to the latest 13F filing for Q4 2025, Chuck Royce's firm, Royce & Associates Lp, owns 207,051 shares of ARS Pharmaceuticals, Inc. (SPRY), valued at approximately $2.41 M.
As of the Q4 2025 filing, ARS Pharmaceuticals, Inc. (SPRY) represents approximately 0.02% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in ARS Pharmaceuticals, Inc. (SPRY) was 929,613 shares, as reported at the end of Q4 2024.